Allergy Asthma 2019 Webinar Series

This series is designed help allergists and other allergy and asthma providers to stay abreast of recent developments in the field of allergy and asthma. 

Topics/Titles

  • Diagnosing and Living with COPD 
  • Nasal Polyps – Seminar on Sinuses, Symptoms and Science
  • Type 2 Inflammation – Severe Asthma and Co-Morbidities
  • Vaping – What We Need to Know 
  • The Next Steps in Peanut Allergy
  • Inhaler Innovation and History: What is the Right Choice for You?
  • Asthma Disparities and Differential Responses to Therapy

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 7 AMA PRA Category 1 CreditsTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support
There is no commercial support for this activity

Target Audience

Primary Care Providers
Felows-in-Training

Learning Objectives

By participating in these webinars, learners should be able to:

  • Identify recent developments in allergy and asthma
  • Translate clinical science principles to clinical practice in patients with asthma and allergic diseases
  • Evaluate diagnostic and therapeutic strategies for treating patients with asthma and allergic diseases
Additional information
Disclosure: 

Faculty, Planners and Disclosures
As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months. The ACCME defines a “commercial interest” as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity.

Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.

Michael Blaiss, MD, Planner
Consultant/Consulting fee: ALK, DBV, Hycor, Merck, Pfizer, Sanofi, Stallergenes Greer, PMD Healthcare

Gary Steven, MD, Presenter
Consultant/Consulting fee: Aimmune, ALK, Regeneron 

Tanya Laidlaw, MD, (Speaker)
Advisory board member/consultant; Sanofi/Regeneron; Consultant/consulting fee – Novartis

Bradley Chipps, MD Speaker
Consultant/Speaker: Astra Zeneca, Circassia, Genentech, Novartis, Regeneron, Sanofi, Teva

Todd Mahr, MD, Speaker
Speaker/Advisory/Honorarium: ALK, GSK, Kaleo, Sanofi, AstraZeneca, Boehringer-Ingelheim, Renegeron, Stellargenes Greer

Julie Wang, MD
Research grants/Consultant: Aimmune, DBV, Regeneron, ALK Abello

J. Allen Meadows, MD, Speaker
Advisory board, Consulting fees: GlaxoSmithKline, Greer, Aimmune
Speaker, honorarium: Optinose, Pfizer, Astra Zeneca

Leroy Graham, MD, Speaker
Speaker/Honoraria: Teva, Integrity CE, ThermoFisher
Co-chair/Advisory Board: Sanofi/Gemzyme

Course summary
Available credit: 
  • 7.00 AMA PRA Category 1 Credit™
Course opens: 
05/23/2019
Course expires: 
12/04/2020
Rating: 
0

Available Credit

  • 7.00 AMA PRA Category 1 Credit™
Please login or create an account to take this course.